Michael Ellis
Ophthalmology · Lenexa, KSNPI 1598127243
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 43.1% of the total. Reporting peaked in 2023 at $22,385 and has fallen 94.2% since, to $1,290 in 2025. Among ophthalmology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $267.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$16K
- Genentech USA, Inc.$8K
- Topcon Healthcare, Inc.$5K
- F. Hoffmann-la Roche AG$3K
- Alimera Sciences, Inc.$3K
- Eyepoint US, Inc.$1K
- plus $2K from 12 others
What the payments were for
- Consulting fees$18,66849%
- Speaking & faculty fees$9,75526%
- Travel & lodging$3,71610%
- Food & beverage$6,05216%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 27 | $16,452 |
| Genentech USA, Inc. | 31 | $7,869 |
| Topcon Healthcare, Inc. | 3 | $5,058 |
| F. Hoffmann-la Roche AG | 2 | $2,892 |
| Alimera Sciences, Inc. | 18 | $2,798 |
| Eyepoint US, Inc. | 3 | $1,063 |
| ANI Pharmaceuticals, Inc. | 13 | $424 |
| AbbVie(2 entities) | 15 | $418 |
| Alcon | 9 | $372 |
| Regeneron Healthcare Solutions, Inc. | 5 | $220 |
| Mallinckrodt Hospital Products Inc. | 2 | $198 |
| Biogen | 5 | $126 |
| Novartis | 1 | $110 |
| Astellas Pharma US Inc | 4 | $72 |
| Bausch & Lomb Americas Inc. | 2 | $43 |
| Coherus Oncology, Inc. | 1 | $35 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,190 in reported general payments places this provider in the 90th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 220 | $7,245 |
| Ketorolac Tromethamine | 58 | $2,437 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $2,352 |
| Ofloxacin | 119 | $1,176 |
| Atropine Sulfate | 21 | $829 |
| Brimonidine Tartrate | 116 | $721 |
| Dorzolamide Hcl | 19 | $361 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $320 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $262 |
| ErythromycinErythromycin Base | 12 | $131 |
| Latanoprost | 18 | $129 |
| Timolol Maleate | 20 | $101 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Lenexa
- Blake CooperLenexa$100K
- Ivan BatlleLenexa$8K
- David DyerLenexa$6K
- Daniel FeilerLenexa$4K
- Steven CohenLenexa$4K
- Gregory FoxLenexa$3K
- Ravi SinghLenexa$2K
- Beatty SuiterLenexa$2K
- Nish PatelLenexa$2K
- Daniel DurrieOverland Park$974K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.